Aclaris Therapeutics, Inc.ACRSNASDAQ
LOADING
|||
Year-over-year operating income growth rate
| Period | Value |
|---|---|
| Q3 2025 | 6.84% |
| Q2 2025 | -1.79% |
| Q1 2025 | 81.86% |
| Q4 2024 | -851.91% |
| Q3 2024 | 18.54% |
| Q2 2024 | 32.10% |
| Q1 2024 | -367.78% |
| Q4 2023 | 87.18% |
| Q3 2023 | 0.75% |
| Q2 2023 | -6.34% |
| Q1 2023 | -2.89% |
| Q4 2022 | -39.31% |
| Q3 2022 | 0.57% |
| Q2 2022 | -11.04% |
| Q1 2022 | 17.41% |
| Q4 2021 | -12.80% |
| Q3 2021 | -12.71% |
| Q2 2021 | 36.89% |
| Q1 2021 | -110.39% |
| Q4 2020 | -29.57% |
| Q3 2020 | 8.05% |
| Q2 2020 | 26.60% |
| Q1 2020 | 11.66% |
| Q4 2019 | 23.23% |
| Q3 2019 | 54.08% |
| Q2 2019 | -33.36% |
| Q1 2019 | 4.36% |
| Q4 2018 | -16.71% |
| Q3 2018 | -4.60% |
| Q2 2018 | -3.33% |
| Q1 2018 | -21.64% |
| Q4 2017 | -35.65% |
| Q3 2017 | -22.63% |
| Q2 2017 | -18.29% |
| Q1 2017 | -11.21% |
| Q4 2016 | -7.54% |
| Q3 2016 | 16.76% |
| Q2 2016 | 1.14% |
| Q1 2016 | -173.62% |
| Q4 2015 | 54.87% |